B-type natriuretic peptide-guided chronic heart failure therapy: A meta-analysis of 11 randomised controlled trials

Heart Lung and Circulation

Volumn 22, Issue 10, 2013, Pages 852-860

  Li, Peng ^a   Luo, Yong ^a   Chen, Yi Ming ^b  

^a PEKING UNIVERSITY SHOUGANG HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

BNP; Chronic heart failure; Prognosis; Rehospitalisation

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARDIOVASCULAR AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART FAILURE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; AGE; BLOOD; CHRONIC DISEASE; HOSPITALIZATION; MEDLINE; MORTALITY;

AGE FACTORS; AGED; CHRONIC DISEASE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MEDLINE; NATRIURETIC PEPTIDE, BRAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84885301115     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2013.03.077     Document Type: Article

References (43)

1. Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006, 12:10-38.
2. de Groote P., Isnard R., Clerson P., Jondeau G., Galinier M., Assyag P., et al. Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The impact-reco programme. Eur J Heart Fail 2009, 11:85-91.
3. Krantz M.J., Tanner J., Horwich T.B., Yancy C., Albert N.M., Hernandez A.F., et al. Influence of hospital length of stay for heart failure on quality of care. Am J Cardiol 2008, 102:1693-1697.
4. Fonarow G.C., Albert N.M., Curtis A.B., Stough W.G., Gheorghiade M., Heywood J.T., et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the registry to improve the use of evidence-based heart failure therapies in the outpatient setting (improve hf). Circulation 2010, 122:585-596.
5. Zugck C., Franke J., Gelbrich G., Frankenstein L., Scheffold T., Pankuweit S., et al. Implementation of pharmacotherapy guidelines in heart failure: experience from the German competence network heart failure. Clin Res Cardiol 2011, 101:263-272.
6. Worster A., Balion C.M., Hill S.A., Santaguida P., Ismaila A., McKelvie R., et al. Diagnostic accuracy of bnp and nt-probnp in patients presenting to acute care settings with dyspnea: a systematic review. Clin Biochem 2008, 41:250-259.
7. Harrison A., Morrison L.K., Krishnaswamy P., Kazanegra R., Clopton P., Dao Q., et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002, 39:131-138.
8. Valle R., Aspromonte N., Carbonieri E., D'Eri A., Feola M., Giovinazzo P., et al. Fall in readmission rate for heart failure after implementation of b-type natriuretic peptide testing for discharge decision: a retrospective study. Int J Cardiol 2008, 126:400-406.
9. van Veldhuisen D.J., Genth-Zotz S., Brouwer J., Boomsma F., Netzer T., Man In T.V.A.J., et al. High- versus low-dose ace inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998, 32:1811-1818.
10. Latini R., Masson S., Anand I., Judd D., Maggioni A.P., Chiang Y.T., et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the valsartan heart failure trial (val-heft). Circulation 2002, 106:2454-2458.
11. Kawai K., Hata K., Takaoka H., Kawai H., Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. Am Heart J 2001, 141:925-932.
12. Tsutamoto T., Wada A., Maeda K., Mabuchi N., Hayashi M., Tsutsui T., et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001, 37:1228-1233.
13. Udelson J.E., Feldman A.M., Greenberg B., Pitt B., Mukherjee R., Solomon H.A., et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail 2010, 3:347-353.
14. Li N., Wang J.A. Brain natriuretic peptide and optimal management of heart failure. J Zhejiang Univ Sci B 2005, 6:877-884.
15. Porapakkham P., Zimmet H., Billah B., Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010, 170:507-514.
16. Felker G.M., Hasselblad V., Hernandez A.F., O'Connor C.M. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009, 158:422-430.
17. Mentz R.J., Felker G.M. Natriuretic peptide-guided therapy for heart failure. Circ J 2011, 75:2031-2037.
18. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
19. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
20. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (n-bnp) concentrations. Lancet 2000, 355:1126-1130.
21. Beck-da-Silva L., de Bold A., Fraser M., Williams K., Haddad H. Bnp-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure. Congest Heart Fail 2005, 11:248-253. quiz 54-5.
22. Jourdain P., Jondeau G., Funck F., Gueffet P., Le Helloco A., Donal E., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the stars-bnp multicenter study. J Am Coll Cardiol 2007, 49:1733-1739.
23. Pfisterer M., Buser P., Rickli H., Gutmann M., Erne P., Rickenbacher P., et al. BNP-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (time-chf) randomized trial. JAMA 2009, 301:383-392.
24. Lainchbury J.G., Troughton R.W., Strangman K.M., Frampton C.M., Pilbrow A., Yandle T.G., et al. N-terminal pro-b-type natriuretic peptide-guided treatment for chronic heart failure: results from the battle scarred (nt-probnp-assisted treatment to lessen serial cardiac readmissions and death) trial. J Am Coll Cardiol 2010, 55:53-60.
25. Eurlings L.W., van Pol P.E., Kok W.E., van Wijk S., Lodewijks-van der Bolt C., Balk A.H., et al. Management of chronic heart failure guided by individual n-terminal pro-b-type natriuretic peptide targets: results of the prima (can pro-brain-natriuretic peptide guided therapy of chronic heart failure improve heart failure morbidity and mortality?) study. J Am Coll Cardiol 2010, 56:2090-2100.
26. Persson H., Erntell H., Eriksson B., Johansson G., Swedberg K., Dahlstrom U. Improved pharmacological therapy of chronic heart failure in primary care: a randomized study of nt-probnp guided management of heart failure-signal-hf (Swedish intervention study-guidelines and nt-probnp analysis in heart failure). Eur J Heart Fail 2010, 12:1300-1308.
27. Berger R., Moertl D., Peter S., Ahmadi R., Huelsmann M., Yamuti S., et al. N-terminal pro-b-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 2010, 55:645-653.
28. Januzzi J.L., Rehman S.U., Mohammed A.A., Bhardwaj A., Barajas L., Barajas J., et al. Use of amino-terminal pro-b-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011, 58:1881-1889.
29. Shah M.R., Califf R.M., Nohria A., Bhapkar M., Bowers M., Mancini D.M., et al. The starbrite trial: a randomized, pilot study of b-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail 2011, 17:613-621.
30. Karlstrom P., Alehagen U., Boman K., Dahlstrom U. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail 2011, 13:1096-1103.
31. Cleland J.G., McMurray J.J., Kjekshus J., Cornel J.H., Dunselman P., Fonseca C., et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: Prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from corona (controlled rosuvastatin multinational trial in heart failure). J Am Coll Cardiol 2009, 54:1850-1859.
32. Masson S., Latini R., Anand I.S., Vago T., Angelici L., Barlera S., et al. Direct comparison of b-type natriuretic peptide (bnp) and amino-terminal probnp in a large population of patients with chronic and symptomatic heart failure: the valsartan heart failure (val-heft) data. Clin Chem 2006, 52:1528-1538.
33. Januzzi J.L., Sakhuja R., O'Donoghue M., Baggish A.L., Anwaruddin S., Chae C.U., et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 2006, 166:315-320.
34. Januzzi J.L. Use of biomarkers to "guide" care in chronic heart failure: what have we learned (so far)?. J Card Fail 2011, 17:622-625.
35. Lustgarten J. Cancer, aging and immunotherapy: lessons learned from animal models. Cancer Immunol Immunother 2009, 58:1979-1989.
36. Ito K., Barnes P.J. COPD as a disease of accelerated lung aging. Chest 2009, 135:173-180.
37. Premoli A., Paschetta E., Hvalryg M., Spandre M., Bo S., Durazzo M. Characteristics of liver diseases in the elderly: a review. Minerva Gastroenterol Dietol 2009, 55:71-78.
38. Wang T.J., Larson M.G., Levy D., Leip E.P., Benjamin E.J., Wilson P.W., et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002, 90:254-258.
39. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., Burnett J.C. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002, 40:976-982.
40. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The solvd investigators. N Engl J Med 1991, 325:293-302.
41. Ghali J.K., Wikstrand J., Van Veldhuisen D.J., Fagerberg B., Goldstein S., Hjalmarson A., et al. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from metoprolol cr/xl randomized intervention trial in chronic hf (merit-hf). J Card Fail 2009, 15:310-318.
42. Hjalmarson A., Goldstein S., Fagerberg B., Wedel H., Waagstein F., Kjekshus J., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol cr/xl randomized intervention trial in congestive heart failure (merit-hf). Merit-hf study group. JAMA 2000, 283:1295-1302.
43. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999, 341:709-717.